Aurobindo Pharma (AUROPHARMA.NS)

Executive Summary

Aurobindo Pharma is a vertically integrated global pharmaceutical company based in Hyderabad, India, with a strong focus on generics, active pharmaceutical ingredients (APIs), and biosimilars. As one of the largest generic drug manufacturers by US prescription volume, the company benefits from a diversified portfolio of over 377 commercial products and operations in 150+ countries. Its robust pipeline includes complex generics and biosimilars (e.g., adalimumab, insulin glargine) that can drive growth amid pricing pressures in the US generics market. However, Aurobindo faces risks from regulatory scrutiny (e.g., FDA warnings on facilities) and foreign exchange volatility. The company’s strong manufacturing capabilities and cost leadership position it well for long-term value creation, though near-term headwinds from price erosion and patent cliffs remain.

Upcoming Catalysts (preview)

• H2 2026FDA approval of biosimilar adalimumab or insulin glargine75% success
• Q3 2026Resolution of US FDA import alert on a key manufacturing facility60% success
• Q4 2026Launch of high-value generic drugs (e.g., Revlimid, Eliquis) under litigation or settlement65% success